Market Intelligence, Clinical Progress, and High-Purity Reagents for Metachromatic Leukodystrophy (MLD) and Lysosomal Storage Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ARSA (Arylsulfatase A) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ARSA Recombinant Protein (WT & Pathogenic Mutants, also Human/Mouse/Cyno) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed for native glycosylation and formylglycine activation. |
View ARSA Products |
| Gene Delivery | ARSA Promise-ORF / Lentivirus Particles Full-length ORF for stable overexpression, lentiviral packaging, and gene therapy screening. |
View ARSA Products |
| Benchmark Ab | Anti-ARSA Reference Antibody / Clinical Benchmark Control High-affinity tool for PK/PD quantification, uptake assays, and immunogenicity (ADA) platform development. |
View ARSA Products |
| Validator | ARSA siRNA Set For knockdown verification and specificity controls in cell-based uptake assays. |
View ARSA Products |
| Related Target: TFRC | TFRC (Transferrin Receptor 1) Blood-Brain Barrier (BBB) transcytosis target for brain-penetrating ARSA fusion proteins. |
View TFRC Products |
| Related Target: SUMF1 | SUMF1 (FGE) Post-translational modifier essential for ARSA catalytic site activation (formylglycine generation). Co-expression improves specific activity. |
View SUMF1 Products |
| Related Target: PSAP | PSAP (Prosaposin) Source of Saposin B, the sphingolipid activator protein required for physiological ARSA substrate presentation. |
View PSAP Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Species translation (Cyno / Mouse preclinical ERT) | Human / Mouse / Cyno ortholog proteins available with >95% purity; sequence verified by mass spec. |
| Lysosomal Enzyme PTMs (Mannose-6-Phosphate) & Uptake | HEK293-expressed ARSA with native N-glycosylation and mannose-6-phosphate pattern; validated for cellular uptake assays. |
| Enzymatic activity requires active-site formylglycine | Mammalian expression system ensures SUMF1-mediated Cα-formylglycine modification; theoretical specific activity supported by correct folding. |
| Immunogenicity (ADA) screening for ERT | High-purity, endotoxin-controlled ARSA antigen (<1 EU/µg) for robust ADA ELISA and SPR assay development. |
| Off-target Sulfatase Selectivity | Homolog panel (ARSB, ARSC, GALNS, IDS) strictly verified by mass spec for selectivity profiling of novel modulators. |
| False Positives / Background Noise | ARSA siRNA and isotype controls included for specificity verification; endotoxin controlled (<1 EU/µg) to prevent artifactual immune activation. |
Live ARSA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for ARSA-deficient Metachromatic Leukodystrophy (MLD) has shifted decisively toward genetic medicine, with ex vivo lentiviral gene therapy (e.g., Orchard Therapeutics' Libmeldy) securing regulatory approvals in major markets. Concurrently, next-generation Enzyme Replacement Therapy (ERT) programs are engineering blood-brain-barrier-penetrant or intrathecal delivery modalities to address peripheral and CNS disease compartments. As first-generation gene therapy establishes clinical proof-of-concept, the next wave of R&D is targeting improved biodistribution, reduction of immunogenicity against the recombinant enzyme, and pharmacological chaperones for residual-activity mutants. The market is pivoting from hematopoietic stem cell transplantation toward one-time genetic correction and engineered fusion proteins for CNS delivery.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (Lentiviral) | Orchard Therapeutics / Kyowa Kirin, Takeda | MLD (Pediatric, early-onset) | Functional ARSA Expression Standards (Need full-length lentivirus, WT & mutant proteins for quantitative QC) |
| Brain-Penetrating ERT (Fusion) | Denali Therapeutics, JCR Pharmaceuticals | CNS Lysosomal Storage (MLD) | Transcytosis Assays (Need HEK293-expressed ARSA and TFRC antigens for BBB modeling) |
| Intrathecal ERT | Takeda (SHP611) | MLD (Late-onset, neurological) | Pharmacokinetics & Uptake (Need M6P-tagged recombinant ARSA, cross-reactive antibodies) |
| Substrate Reduction Therapy | Takeda, Idorsia | MLD (Adjunct) | Off-target Sulfatase Selectivity (Need ARSA vs ARSB/GALNS selectivity panels) |
| Pharmacological Chaperones | Rare Disease Academia / Industry | MLD (late-onset variants) | Mutant vs WT Protein Stability (Need pathogenic mutant panel: R84Q, P426L, A212V) |